You are here

Article Text

Article menu

Download PDFPDF

Images in…
Long-term adverse effects of intramuscular oil injection
Free
  1. Jacob Juel1,
  2. Dorthe Vestergaard Grejsen2,
  3. Manan Pareek3
  1. 1Department of Plastic Surgery, Aalborg Universitetshospital, Aalborg, Denmark
  2. 2Department of Pathology, Zealand University Hospital, Roskilde, Denmark
  3. 3Heart & Vascular Center, Brigham and Women's Hospital, Boston, Massachusetts, USA
  1. Correspondence to Dr Manan Pareek, mananpareek{at}dadlnet.dk

https://doi.org/10.1136/bcr-2017-220698

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Description

    A 33-year-old male former bodybuilder presented with painful deformities located to his arms. Roughly a decade ago, he had injected liquid paraffin into his biceps and triceps as a shortcut to achieve muscular enhancement. Today, some of the oil has descended to the forearms, leaving him with painful swellings (paraffinomas) (figure 1) and paraesthesia. MRI revealed localised intramuscular distribution of liquid paraffin in the upper arm muscles (figure 2) and diffuse and localised subcutaneous distribution in the forearms. The patient is currently reviewed regularly as an outpatient and is still able to work as an engineer. A careful history has not revealed any overt systemic complications related to the injections and, so far, he has not required active treatment for his condition.

    Figure 1
    Figure 1

    Muscular hypertrophy and swellings (arrows) after liquid paraffin injection.

    Figure 2
    Figure 2

    MRI showing localised intramuscular distribution of liquid paraffin (arrows) in the upper arm.

    Site enhancement oils or muscle fillers are liquid compounds of medium-chain triglycerides, local anaesthetics and alcohol that can be injected into muscles to enlarge their size or to alter their shape.1–3 Commonly utilised options include paraffin and synthol.1 The medical uses of paraffin include skin care and as a laxative, but when injected intramuscularly, complications such as paraffinomas (chronic sclerosing lipogranulomas), ulcerations, infection, systemic embolism and an often-negated irreversible muscle damage may develop within weeks or up to several years after abuse.2 Sadly, no curative treatment is available, but surgery, corticosteroids, compressions or antibiotics may be required, depending on the presentation.3 Surgery should be reserved for the most severe cases, as it may further reduce functional performance. Vigilance is imperative for surgeons treating this condition, but even more so for those considering such cosmetic doping, given the possibility of permanent destructive complications, even with short-term use.2

    Learning points

    • Site enhancement oils, for example, paraffin and synthol, are injected into muscles for augmentation purposes.

    • Destructive complications may develop several years after (ab)use.

    • No curative treatment is available, but surgery may be required for palliative purposes.

    References

    1. ↵
      1. Figueiredo VC,
      2. Silva PR
      . Cosmetic doping-when anabolic-androgenic steroids are not enough. Subst Use Misuse 2014;49:1163–7.doi:10.3109/10826084.2014.916522
      OpenUrl
    2. ↵
      1. Banke IJ,
      2. Prodinger PM,
      3. Waldt S, et al
      . Irreversible muscle damage in bodybuilding due to long-term intramuscular oil injection. Int J Sports Med 2012;33:829–34.doi:10.1055/s-0032-1311582
      OpenUrlCrossRefPubMed
    3. ↵
      1. Schäfer CN,
      2. Hvolris J,
      3. Karlsmark T, et al
      . Muscle enhancement using intramuscular injections of oil in bodybuilding: review on epidemiology, complications, clinical evaluation and treatment. European Surgery 2012;44:109–15.doi:10.1007/s10353-011-0033-z
      OpenUrl
    View Abstract

    Footnotes

    • Contributors JJ wrote the initial draft. JJ, DVG and MP participated in collecting patient data, reviewing the literature, interpretation of clinical findings, critical revision of the manuscript for important intellectual content and approval of the final version.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.